PTHS

Pelthos Therapeutics Inc. (PTHS) 10Y Growth Potential Analysis (2026)

Invetso Score: 3/10 — Weak · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Revenue Growth Drivers

Score: 3.2 (Weak)

No five-year revenue, EPS, or FCF CAGR is provided, limiting evidence of repeatable compounding versus peers with disclosed multi-year growth histories.

TTM ROIC is deeply negative at -49.4%, indicating current capital deployment is not yet converting into scalable revenue expansion like stronger peer platforms.

R&D intensity is only 3.0% of revenue, suggesting limited reinvestment capacity for product or service expansion relative to peers with higher innovation spend.

Negative EV/EBITDA and negative interest coverage imply earnings quality is weak, reducing internally funded growth capacity versus better-capitalized peers.

Market Tailwinds

Score:

No segment mix, share data, or addressable-market evidence is provided, so durable demand tailwinds cannot be established versus peers with clearer end-market exposure.

The company’s current economics appear stressed, which weakens its ability to capture industry growth even if external demand improves relative to healthier peers.

A 412.8-day cash conversion cycle signals slow monetization of sales, limiting the pace at which demand can translate into scalable revenue growth.

Absent filing-based evidence of expanding end markets, the growth profile remains more constrained than peers with proven multi-year demand conversion.

Scalability Expansion

Score:

Capex-to-revenue is only 0.7%, but the negative ROIC suggests low-return scaling rather than efficient expansion versus peers with proven operating leverage.

Negative net debt to EBITDA reflects balance-sheet support, yet it does not offset the lack of demonstrated scalable earnings conversion.

The very long cash conversion cycle indicates working-capital drag, which structurally slows expansion and reduces reinvestment speed relative to peers.

Without evidence of rising margins, share gains, or multi-year revenue CAGR, scalability remains unproven and below stronger peer compounding models.

Constraints Limitations

Score:

Negative ROIC is the clearest structural constraint, because it implies incremental capital is not currently producing durable revenue or profit growth.

The 412.8-day cash conversion cycle creates persistent working-capital strain, limiting how quickly the business can scale versus peers with faster cash turns.

Negative interest coverage indicates financing flexibility is constrained, which can cap long-term expansion even if growth opportunities emerge.

Missing historical growth metrics and segment data prevent evidence of durable compounding, leaving the company weaker than peers with visible scaling trajectories.

Overall Score

Score:

PTHS shows structurally constrained long-term growth capacity because current capital deployment is unproductive, cash conversion is slow, and peer-comparable evidence of scalable compounding is absent.

Score Driver: Negative Roic

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Pelthos Therapeutics Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →